Skip to Content
US Videos

Will Reform Put a Target on Pharma's Back?

Morningstar's Damien Conover says that current reform proposals are more like a slingshot than a rifle aimed at pharmaceutical companies--which are currently priced for a worst-case scenario.

Alex Morozov: Hi, I'm Alex Morozov, the associate director of the health-care team here at Morningstar. With some sort of health-care reform imminent in the near future, the pharmaceutical sector is viewed by many to have a target on its back. With me is our senior pharmaceutical analyst, Damien Conover, to discuss potential reform proposals and the impact it will have on the pharmaceutical stocks.

Welcome, Damien.